NMPA

Beyond's analysis on NMPA

• 2026-07-15 — Harbour BioMed and Kelun-Biotech secure NMPA IND clearance for HBM7575/SKB575, advancing a novel asthma biologic into clinical trials in China

Recent news mentioning NMPA

• 2026-08-21 — Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
• 2026-08-18 — Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
• 2026-08-07 — Alebund's AP301 NDA Accepted for Review by China's NMPA
• 2026-07-30 — NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC

Appears alongside

• NDA
• BioMed
• IND
• China
• AP301
• TNBC

Browse the full archive →